Early effects of unfractionated heparin on clinical and radiological signs and D-dimer levels in patients with COVID-19 associated pulmonary embolism: An observational cohort study

Dutch COVID & Thrombosis Coalition (DCTC), L I van der Wal, L J M Kroft, L F van Dam, C M Cobbaert, J Eikenboom, M V Huisman, H J F Helmerhorst, F A Klok, E de Jonge, Dutch COVID & Thrombosis Coalition (DCTC), L I van der Wal, L J M Kroft, L F van Dam, C M Cobbaert, J Eikenboom, M V Huisman, H J F Helmerhorst, F A Klok, E de Jonge

No abstract available

Keywords: COVID-19; D-dimer; Pulmonary embolism; Unfractionated heparin.

Conflict of interest statement

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: MV Huisman received grants from ZONMW, Bayer Health Care, Pfizer-BMS, Boehringer-Ingelheim, Leo Pharma, all outside the submitted work. J Eikenboom received research support from CSL Behring and he has been teacher on educational activities of Roche, all outside the submitted work. FA Klok reports research support from Bayer Health Care, Bristol-Myers Squibb, Boehringer-Ingelheim, MSD, Daiichi-Sankyo, Actelion, the Dutch thrombosis association, The Netherlands Organisation for Health Research and Development and the Dutch Heart foundation, all outside the submitted work. The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
a. Course of D-dimer levels before and after start of heparin. D-dimer levels from 2 days before the start of UFH until 21 days after start of UFH or until ICU discharge are shown. T = 0 represents the start of heparin for each individual patient, which is marked by the dotted line. b. Percentage change of D-dimer levels for different time frames before and after start of heparin. All samples were taken at 6:00 A.M. For every patient T = 0 represents the time of blood sampling at 6:00 AM of the day that heparin was started. The horizontal lines represent the percentage change in that time frame for each individual patient. The arrow represents the mean actual time of start of heparin, on average 9 h (SD4.9) after blood sampling.

References

    1. Nopp S., Moik F., Jilma B., Pabinger I., Ay C. Risk of venous thromboembolism in patients with COVID-19: a systematic review and meta-analysis. Research and Practice in Thrombosis and Haemostasis. 2020;4(7):1178–1191.
    1. Levi M., De Jonge E., Van Der Poll T. New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology. Ann. Med. 2004;36(1):41–49.
    1. Connors J.M., Levy J.H. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033–2040.
    1. Van Dam L.F., Kroft L.J.M., Van Der Wal L.I., Cannegieter S.C., Eikenboom J., De Jonge E., et al. Clinical and computed tomography characteristics of COVID-19 associated acute pulmonary embolism: a different phenotype of thrombotic disease? Thromb. Res. 2020;193:86–89.
    1. Qanadli S.D., El Hajjam M., Vieillard-Baron A., Joseph T., Mesurolle B., Oliva V.L., et al. New CT index to quantify arterial obstruction in pulmonary embolism: comparison with angiographic index and echocardiography. AJR Am. J. Roentgenol. 2001;176(6):1415–1420.
    1. Tang N., Bai H., Chen X., Gong J., Li D., Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J. Thromb. Haemost. 2020;18(5):1094–1099.
    1. Dorffler-Melly J., de Jonge E., Pont A.C., Meijers J., Vroom M.B., Buller H.R., et al. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet. 2002;359(9309):849–850.
    1. Pesavento R., Ceccato D., Pasquetto G., Monticelli J., Leone L., Frigo A., et al. The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: the Padua province experience. J. Thromb. Haemost. 2020;18(10):2629–2635.
    1. Huisman M.V., Barco S., Cannegieter S.C., Le Gal G., Konstantinides S.V., Reitsma P.H., et al. Pulmonary embolism. Nature Reviews Disease Primers. 2018;4:18028.
    1. Ende-Verhaar Y.M., Cannegieter S.C., Vonk Noordegraaf A., Delcroix M., Pruszczyk P., Mairuhu A.T., et al. Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature. Eur. Respir. J. 2017;49(2)

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner